Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Why Acumen Pharmaceuticals Stock Is Soaring Today

Published 28/09/2022, 16:19
© Reuters.  Why Acumen Pharmaceuticals Stock Is Soaring Today
BIIB
-
BIIB34
-
ABOS
-

Acumen Pharmaceuticals Inc (NASDAQ: ABOS) shares are trading higher Wednesday after Biogen Inc (NASDAQ: NASDAQ:BIIB) and Eisai Co (Pink: ESALY) announced that the Phase 3 clarity study of lecanemab met its primary endpoint.

Lecanemab is an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease. The companies said Lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results.

Find Out More: What In The World Is Going On With Biogen (BIIB) Shares?

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease.

Shares of several companies with Alzheimer's programs are trading higher following the update from Biogen and Eisai.

ABOS Price Action: Acumen is making new 52-week highs on Wednesday.

The stock was up 93.2% at $9.05 at time of publication, according to Benzinga Pro.

Photo: Raman Oza from Pixabay.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.